HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Rivastigmine

HCID 77991
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
123441-03-2
Standard SMILES
CCN(C)C(=O)Oc1cccc([C@H](C)N(C)C)c1
InChIKey
XSVMFMHYUFZWBK-NSHDSACASA-N
Molecular formula
C14H22N2O2
Average molar mass
250.34 g/mol
Monoisotopic mass
250.16812795

Overview

Rivastigmine is a carbamate ester obtained by formal condensation of the carboxy group of ethyl(methyl)carbamic acid with the phenolic OH group of 3-[(1S)-1-(dimethylamino)ethyl]phenol. A reversible cholinesterase inhibitor. It has a role as an EC 3.1.1.8 (cholinesterase) inhibitor, a cholinergic drug and a neuroprotective agent. It is a carbamate ester and a tertiary amino compound. It is a conjugate base of a rivastigmine(1+).

Names & identifiers

Preferred name
Rivastigmine
IUPAC
[3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate
English name
Rivastigmine
Molecular formula
C14H22N2O2
Molecular weight
250.34

Names & synonyms

rivastigmine123441-03-2PrometaxENA 713 free baseNimvastidRivastigmine Tevarivastigmine hexalRivastigminaRivastigmine sandozSDZ-ENA-713Rivastigmine Transdermal SystemSDZ-212-713
Show more names
RIVASTIGMINE HYDROGEN TARTRATEmineEXELONRivastigmine baseRivastigKabaratincabalatineRevastigmineRivastigiMine
(S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamatem-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamateONO-2540PKI06M3IW0SDZ 212-713ENA-713D3-[(1S)-1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamateSDZ-212713

Database identifiers

CAS
123441-03-2
PubChem CID
77991
DTXSID
DTXSID7023564
ChEMBL
CHEMBL636
ChEBI
CHEBI:8874
UNII
PKI06M3IW0
EC Number
602-936-0
Nikkaji
J982.502I

Properties

Computed structural properties

XLogP
2.3
Topological polar surface area
32.8 Ų
Hydrogen bond donors
0
Hydrogen bond acceptors
3
Rotatable bonds
5
Heavy atoms
18
Formal charge
0
Complexity
269

Experimental & physicochemical properties

Drugs · 2 items

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Acetylcholinesterase inhibitor

LogP2.3
Solubility2.04e+00 g/L
Human Drugs · 6 items

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

Physical DescriptionSolid
Dissociation Constants · 2 items

8.8

8.99

Collision Cross Section165 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

Physicochemical properties

alpha
20 · D20 -32.1° (c = 5 in ethanol)
Boiling point
316.2 · 316.2±34.0 °C(Predicted)
Density
1.038 · 1.038±0.06 g/cm3(Predicted)
Flash point
145 ℃ · 145℃
storage temp.
-20 °C · Sealed in dry,Store in freezer, under -20°C
solubility
Chloroform (Sparingly), Ethyl Acetate (Slightly)
form
Powder
pka
8.99 · pKa 8.99 (Uncertain)
color
Colorless to light yellow
Major Application
pharmaceutical (small molecule)
InChI
InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1
InChIKey
XSVMFMHYUFZWBK-NSHDSACASA-N
SMILES
C(OC1=CC=CC([C@@H](N(C)C)C)=C1)(=O)N(CC)C
CAS DataBase Reference
123441 · 123441-03-2(CAS DataBase Reference)
EWG's Food Scores
1 · 1
FDA UNII
6 M3IW0 · PKI06M3IW0
NCI Drug Dictionary
Exelon
ATC code
6 DA03 · N06DA03
Comptox DTXSID
7023564 · DTXSID7023564
UNSPSC Code
41116107 · 41116107
NACRES
24 · NA.24
Protein binding
40 % · 40%
Excreted unchanged in urine
0 · 0 (>90 as pharmacologically inactive metabolites)
Volume of distribution
1.8 · 1.8-2.7(L/kg)
Biological half-life
1 · 1 / -
Symbol(GHS)
6 · GHS06,GHS09
Signal word
Danger
Hazard statements
300 · H300-H411
Precautionary statements
264 · P264-P270-P273-P301+P310-P391-P405
RIDADR
2810 · UN 2810 6.1 / PGIII
WGK Germany
3 · WGK 3
HS Code
2924296000 · 2924296000
Storage Class
6.1 A · 6.1A - Combustible acute toxic Cat. 1 and 2very toxic hazardous materials
Hazard Classifications
2 OralAquatic · Acute Tox. 2 OralAquatic Chronic 2

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 5 items

This chemical does not meet GHS hazard criteria for 6.2% (1 of 16) of reports.

Danger

H300 (31.2%): Fatal if swallowed [Danger Acute toxicity, oral]

P261, P264, P270, P271, P273, P280, P301+P316, P302+P352, P304+P340, P317, P321, P330, P362+P364, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 16 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Hazard Classes and CategoriesAcute Tox. 2 (31.2%)

Toxicology

Hepatotoxicity · 1 item

In large placebo controlled trials, rivastigmine therapy was not associated with an increased rate of serum enzyme elevations compared to placebo treatment and no instances of clinically apparent liver injury with jaundice were reported. Nevertheless, since its introduction into clinical use, rivastigmine (administered by transdermal patch) has been implicated in at least one report of clinically apparent hepatotoxicity with mild jaundice. The time to onset was 2 months and the serum enzyme elevations had a mildly hepatocellular pattern. Mild rash and eosinophilia were also present, but autoimmune features were not. Recovery was complete within 5 weeks of drug discontinuation.

Adverse Effects · 1 item

Adverse effects of rivastigmine have received thorough study as it has been on the market for some time. The main adverse effects associated with the use of rivastigmine are gastrointestinal. The primary symptoms are nausea and vomiting. These acute effects primarily occur during the initial dose-escalation phase of therapy with upward dose titration of the drug to achieve a therapeutic dose. These events can be minimized using a slow titration schedule and taking the medication with food if prescribing an oral formulation. In a study done to analyze the safety and tolerability of cholinesterase inhibitors used to treat Alzheimer dementia, researchers found rivastigmine to be the drug to have the highest rate of gastrointestinal side effects.

Toxicity Summary · 1 item

Toxicity to the drug, while rare, should be carefully monitored. Common toxicity manifestations include severe gastrointestinal reactions, allergic cutaneous reactions, and central nervous system effects. All cutaneous reactions due to usage of the patch should prompt immediate removal of the patch for at least 48 hours before reapplying in a new area. Therapy should be discontinued if symptoms last longer than 48 hours or a severe cutaneous reaction occurs.

Drug Induced Liver Injury · 5 items

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

rivastigmine

DILI Positive

Oral

DOI:10.1016/j.drudis.2019.09.022

Safety data

wgk
WGK 3
ridadr
UN 2810 6.1 / PGIII
hs_code
2924296000
Signal word
Danger
Symbol(GHS)
GHS06,GHS09
Storage Class
6.1A - Combustible acute toxic Cat. 1 and 2very toxic hazardous materials
Hazard statements
H300-H411
Hazard Classifications
Acute Tox. 2 OralAquatic Chronic 2
Precautionary statements
P264-P270-P273-P301+P310-P391-P405

Chemistry & industry

Pharmacology

ATC Code · 3 items

N06DA03

N - Nervous system

QN - Nervous system

Protein Binding40%
Pharmacodynamics · 1 item

Rivastigmine is a parasympathomimetic and a reversible cholinesterase inhibitor. An early pathophysiological feature of Alzheimer's disease that is associated with memory loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Tacrine is postulated to exert its therapeutic effect by enhancing cholinergic function. While the precise mechanism of rivastigmine's action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. If this proposed mechanism is correct, rivastigmine's effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact.

Mechanism of Action · 1 item

Rivastigmine is a carbamate derivative that is structurally related to physostigmine, but not to donepezil and tacrine. The precise mechanism of rivastigmine has not been fully determined, but it is suggested that rivastigmine binds reversibly with and inactivates chlolinesterase (eg. acetylcholinesterase, butyrylcholinesterase), preventing the hydrolysis of acetycholine, and thus leading to an increased concentration of acetylcholine at cholinergic synapses. The anticholinesterase activity of rivastigmine is relatively specific for brain acetylcholinesterase and butyrylcholinesterase compared with those in peripheral tissues.

Biological Half-Life1.5 hours
Metabolism/MetabolitesRivastigmine is rapidly metabolized by cholinesterase-mediated hydrolysis.
FDA Pharmacological Classification · 6 items

PKI06M3IW0

RIVASTIGMINE

Established Pharmacologic Class [EPC] - Cholinesterase Inhibitor

Mechanisms of Action [MoA] - Cholinesterase Inhibitors

Rivastigmine is a Cholinesterase Inhibitor. The mechanism of action of rivastigmine is as a Cholinesterase Inhibitor.

RIVASTIGMINE

MeSH Pharmacological Classification · 2 items

Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.

Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids.

Absorption, Distribution and Excretion · 3 items

Rivastigmine is extensively metabolized primarily via cholinesterase-mediated hydrolysis to the decarbamylated metabolite NAP226-90. Renal excretion of the metabolites is the major route of elimination. Less than 1% of the administered dose is excreted in the feces.

1.8 to 2.7 L/kg

renal cl=2.1-2.8 L/hr

Cellular LocationsCytoplasm

Uses & manufacturing

UsesUse (kg; approx.) in Germany (2009): >100
Applications · 3 items

HistoryRivastigmine was discovered by Marta Weinstock-Rosin of the Department of Pharmacology at the Hebrew University of Jerusalem and sold to Novartis by Yissum for commercial development. Rivastigmine, sold under the brand name Exelon among others, is an acetylcholinesterase inhibitor used for the treatment of dementia associated with Alzheimer's disease and with Parkinson's disease.

UsesAntidepressant

General DescriptionRivastigmine (Exelon, EA 713) is apseudoirreversible noncompetitive carbamate inhibitor ofAChE. Although the half-life is approximately 2 hours,the inhibitory properties of this agent last for 10 hours becauseof the slow dissociation of the drug from the enzyme.The Food and Drug Administration (FDA) approved its usein mild-to-moderate Alzheimer disease in April 2000. InJuly 2007, rivastigmine was granted approval for use inmanaging mild-to-moderate dementia associated withParkinson disease.

Upstream & downstream products

Upstream raw materials

(S)-1-(3-(ethyl(methyl)carbamoyloxy)phenyl)-N,N-dimethyl-N-((S)-1-phenylethyl)ethanaminium iodideRivastigmine hydrochlorideCarbamic acid, N-ethyl-N-methyl-, 3-[(1S)-1-aminoethyl]phenyl ester1257519-35-9Methanamine, N-(benzoyloxy)-N-methyl-3-(1-(Dimethylamino)ethyl]phenol3-[(1S)-1-(Dimethylaminoethyl)]phenolEthylmethyl-carbamic chlorideRivastigmine EP Impurity E3-(1-hydroxyethyl)phenyl ethyl(methyl)carbamate(R)-3-(1-hydroxyethyl)phenylethyl(methyl)carbamate

Additional notes

DefinitionChEBI: A carbamate ester obtained by formal condensation of the carboxy group of ethyl(methyl)carbamic acid with the phenolic OH group of 3-[(1S)-1-(dimethylamino)ethyl]phenol. A reversible cholinesterase inhibitor.

Related reactions

3 records
New reaction record
HRID 532100 reaction equation
HRID 532100As product
HRID 907502 reaction equation
HRID 907502As reactant
HRID 1425636 reaction equation
HRID 1425636As product

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes